CD28 Down-Regulation on Circulating CD4 T-Cells Is Associated with Poor Prognoses of Patients with Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Although the etiology of idiopathic pulmonary fibrosis (IPF) remains perplexing, adaptive immune activation is evident among many afflicted patients. Repeated cycles of antigen-induced proliferation cause T-cells to lose surface expression of CD28, and we hypothesized this process might also occur in IPF. METHODOLOGY/PRINCIPAL FINDINGS: Peripheral blood CD4 T-cells from 89 IPF patients were analyzed by flow cytometry and cytokine multiplex assays, and correlated with clinical events. In comparison to autologous CD4(+)CD28(+)cells, the unusual CD4(+)CD28(null) lymphocytes seen in many IPF patients had discordant expressions of activation markers, more frequently produced cytotoxic mediators perforin (2.4+/-0.8% vs. 60.0+/-7.4%, p<0.0001) and granzyme B (4.5+/-2.8% vs.74.9+/-6.5%, p<0.0001), produced greater amounts of many pro-inflammatory cytokines, and less frequently expressed the regulatory T-cell marker FoxP3 (12.9+/-1.1% vs. 3.3+/-0.6% p<0.0001). Infiltration of CD4(+)CD28(null) T-cells in IPF lungs was confirmed by confocal microscopy. Interval changes of CD28 expression among subjects who had replicate studies were correlated with conterminous changes of their forced vital capacities (r(s) = 0.49, p = 0.012). Most importantly, one-year freedom from major adverse clinical events (either death or lung transplantation) was 56+/-6% among 78 IPF patients with CD4(+)CD28(+)/CD4(total)>or=82%, compared to 9+/-9% among those with more extensive CD28 down-regulation (CD4(+)CD28(+)/CD4(total)<82%) (p = 0.0004). The odds ratio for major adverse events among those with the most extensive CD28 down-regulation was 13.0, with 95% confidence intervals 1.6-111.1. CONCLUSIONS/SIGNIFICANCE: Marked down-regulation of CD28 on circulating CD4 T-cells, a result of repeated antigen-driven proliferations, is associated with poor outcomes in IPF patients. The CD4(+)CD28(null) cells of these patients have potentially enhanced pathogenic characteristics, including increased productions of cytotoxic mediators and pro-inflammatory cytokines. These findings show proliferative T-cell responses to antigen(s) resulting in CD28 down-regulation are associated with progression and manifestations of IPF, and suggest assays of circulating CD4 T-cells may identify patients at greatest risk for clinical deterioration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






![Figure 7 Flow cytometry methodology (see also references 20, 52). Aliquots of fresh, live peripheral blood mononuclear cells (PBMNC) were stained with anti-CD4-allophycocyanin (APC), anti-CD28-fluorescein isothiocyanate (FITC), and phycoerythrin (PE)-conjugated antibodies against other cell epitopes. A.) Ten thousand (10,000) or more live cells were selected for further study, based their side scatter (SSC) and forward scatter (FSC) characteristics (G1). B.) The brightly staining CD4 cells among these also expressed CD3 (Cy-Chrome) and, thus, are T-cells [52]. C.) These CD4 T-cells were further characterized based on their expression of CD28. The proportions of CD4+CD28+ T-cells among the total CD4+ T-cell population (upper left and upper right quadrants) defines the CD28%. The respective proportions of CD4+CD28+ and CD4+CD28null cells that co-expressed other cell determinants of interest (in this case MHC Class II [DR]) were quantitated. Numbers within the delineated region/quadrants denote the proportions of cells with these respective characteristics.](https://figures.cochat.ai/paper-figures/974f8f991dff4f4c9356985eebda3f1e/cd28-down-regulation-on-circulating-cd4-t-cells-is-associated-with-poor-figure-7.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“reduced expression of the costimulatory molecule CD28 on circulating T cells was seen to be a predictor of poor outcomes (130).”
From The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis (2018) · cites this paper as [130]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sakaguchi, S. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141122 · Cited by 3,306 · cited 1×
“(Treg), widely regarded as having important roles in dampening adaptive immune responses against antigens [16], are diminished in both the circulation and broncholavolar lavage returns of IPF patients [17].”
BackgroundIdiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Sharpe, A. H., & Freeman, G. J. (2002) · Nature Reviews Immunology · doi:10.1038/nri727 · Cited by 1,712 · cited 2×
“Nearly all normal CD4 T-lymphocytes express CD28 on their cell surfaces [38], and finding significant proportions of circulating CD4CD28 T-cells is distinctly abnormal [19–34].”
BackgroundIdiopathic Pulmonary Fibrosis: Clinical Relevance of Pathologic Classification
KATZENSTEIN, A.-L. A., & MYERS, J. L. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.4.9707039 · Cited by 1,261
Editorial: Cerebral Palsy—the International Consensus Statement
Clements, R. V., & Simanowitz, A. (2000) · Clinical Risk · doi:10.1177/135626220000600401 · Cited by 856
international consensus statement
Clements, R. V., & Simanowitz, A. (2000) · Cited by 852
Changes in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Tai, X., Cowan, M., Feigenbaum, L., & Singer, A. (2005) · Nature Immunology · doi:10.1038/ni1160 · Cited by 613
Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes.
Liuzzo, G., Goronzy, J. J., Yang, H., Kopecky, S. L., Holmes, D. R., Frye, R. L., & Weyand, C. M. (2000) · Circulation · doi:10.1161/01.cir.101.25.2883 · Cited by 552 · cited 10×
“These data demonstrate that the CD4CD28 T-cells of IPF patients exhibit unusual characteristics (Figure 1B and Figure 2) that are very similar to analogous cells isolated from other patient populations with chronic immunologic diseases [19–34].”
BackgroundResultInfluential
Cited by
Items 101–200 of 209
Lacy, S. H., Epa, A. P., Pollock, S. J., Woeller, C. F., Thatcher, T. H., Phipps, R. P., & Sime, P. J. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00565.2016 · Cited by 24
“For example, gene profiling studies in circulating PBMCs have shown that reduced expression of genes involved in T cell activation is associated with shortened transplant-free survival in IPF patients (23, 25), whereas downregulated CD28 expression on circulating CD4 T cells is reflective of CD4 CD28 T cell infiltrate…”
Idiopathic pulmonary fibrosis: Diagnosis, biomarkers and newer treatment protocols
Patel, H., Shah, J. R., Patel, D., Avanthika, C., Jhaveri, S., & Gor, K. (2022) · Disease-a-Month · doi:10.1016/j.disamonth.2022.101484 · Cited by 25
Acute Exacerbations of Interstitial Lung Diseases: Focus on Biomarkers
Drakopanagiotakis, F., Markart, P., & Steiropoulos, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210196 · Cited by 25
“Decreased serum CD28+ CD4+ T cells, as well as increased CD8+ T-cell numbers in lung biopsies from patients with IPF, have been associated with prognosis and disease severity [58,59].”
BackgroundMendoza, N., Casas-Recasens, S., Olvera, N., Hernández‐González, F., Cruz, T., Albacar, N., Alsina‐Restoy, X., Frino-García, A., López-Saiz, G., Robres, L., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813832 · Cited by 23
“Previous reports have shown an abundance of CD8+CD28− T cells in explanted IPF lung tissues (end stage disease) and reported that they predict poor prognosis [9,10,22].”
BackgroundResultAntibody-mediated depletion of CCR10+EphA3+ cells ameliorates fibrosis in IPF
Hohmann, M. S., Habiel, D. M., Espíndola, M. S., Huang, G., Jones, I. C., Narayanan, R., Coelho, A. L., Oldham, J. M., Noth, I., Ma, S., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.141061 · Cited by 23
“Adding to this complexity is the fact that lymphocytes (8, 9); myeloid (10–13), epithelial (14, 15), endothelial (16–18), and mesenchymal cells (19–23); as well as several signaling pathways propagated in these cells (9,”
BackgroundCésar, E. C., López, L. L., Lara, E., Juan, M. V. H.-S., Romero, C. P., Palencia, J. L. R. S., Martín‐Montañez, E., & Garcia‐Fernandez, M. I. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10143167 · Cited by 21
“Furthermore, telomere shortening has been associated with poor prognosis and increased risk of death [35,36].”
BackgroundKumar, M., Zaman, K., Das, S., Goyary, D., Pathak, M. P., & Chattopadhyay, P. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114861 · Cited by 22
Hernández‐González, F., Pietrocola, F., Cameli, P., Bargagli, E., Prieto‐González, S., Cruz, T., Mendoza, N., Rojas, M. M., Serrano, M., Agustí, A. G. N., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147554 · Cited by 19
“Additionally, proliferative T cell responses leading to CD28 downregulation are associated with IPF progression, suggesting that assessing circulating CD4 T cells could identify patients prone to deterioration [59].”
BackgroundIntrapulmonary Autoantibodies to HSP72 Are Associated with Improved Outcomes in IPF
Mills, R., Mathur, A., Nicol, L. M., Walker, J. J., Przybylski, A. A., MacKinnon, A. C., Howie, S., Wallace, W. A., Dransfield, I., & Hirani, N. (2019) · Journal of Immunology Research · doi:10.1155/2019/1845128 · Cited by 21
Yoshida, T., Ohnuma, A., Horiuchi, H., & Harada, T. (2011) · Journal of Toxicologic Pathology · doi:10.1293/tox.24.9 · Cited by 21
Davis, J. M., Knutson, K. L., Skinner, J. A., Strausbauch, M. A., Crowson, C. S., Therneau, T. M., Wettstein, P. J., Matteson, E. L., & Gabriel, S. E. (2012) · Arthritis Research & Therapy · doi:10.1186/ar3706 · Cited by 24
“Further, CMV-specific CD28 T cells have a known association with the systemic complications of RA, including lung disease, vasculitis, cardiovascular disease and mortality, highlighting their potential role in the pathophysiology of RA [65,67,77,78].”
BackgroundT cell Co-Stimulatory molecules ICOS and CD28 stratify idiopathic pulmonary fibrosis survival
Bonham, C. A., Hrusch, C. L., Blaine, K. M., Manns, S. T., Vij, R., Oldham, J. M., Churpek, M. M., Strek, M. E., Noth, I., & Sperling, A. I. (2019) · Respiratory Medicine X · doi:10.1016/j.yrmex.2019.100002 · Cited by 25
Correlates of survival after autoantibody reduction therapy for acute IPF exacerbations
Kulkarni, T., Valentine, V. G., Fei, F., Tran-Nguyen, T. K., Quesada-Arias, L. D., Mkorombindo, T., Pham, H. P., Simmons, S. C., Dsouza, K. G., Luckhardt, T., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0260345 · Cited by 18
Self-citationMolecular Biomarkers in Interstitial Lung Diseases
Lauretis, A. D., & Renzoni, E. A. (2014) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-014-0109-0 · Cited by 21
“Down-regulation of cluster of differentiation (CD)-28 on circulating CD4 T cells, a marker of effector memory T cells that develop as a result of repeated antigen-driven proliferations, has also been associated with decreased lung function and survival in IPF patients [110].”
BackgroundPTK2-associated gene signature could predict the prognosis of IPF
Feng, A., Caro, Y. M., Gardner, C., Grischo, G., Liang, Y., Wickremasinghe, P. D., Polmann, M. B., Kala, M., Marlowe, T. A., Black, S. M., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02582-4 · Cited by 20
“Since immune cell activation plays a crucial role in the development and progression of IPF [23–27], we analyzed estimated proportions of immune cells in these two groups to evaluate immune cell regulation in the high-risk group.”
BackgroundHe, F., Zhou, A., & Feng, S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197658 · Cited by 17
O’Flaherty, B. M., Matar, C. G., Wakeman, B. S., Garcia, A., Wilke, C. A., Courtney, C. L., Moore, B. B., & Speck, S. H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135719 · Cited by 18
“Some researchers have shown an association between CD8 T cells and worsening clinical symptoms or disease progression [55–57]; while other studies have indicated CD4 T cells [58] and their activation [59] negatively impact disease status.”
BackgroundBaroke, E., Gauldie, J., & Kolb, M. R. J. (2013) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2013.838015 · Cited by 18
Yadav, A. K., Lal, A., & Jha, V. (2012) · Nephron Clinical Practice · doi:10.1159/000338352 · Cited by 20
Lee, J. H., Jang, J. H., Lee, S., & Her, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412126 · Cited by 17
“In IPF, the absence of costimulatory molecules such as CD80/86 on fibroblasts and low expression of CD28 on T cells suggest a state of T-cell anergy or functional unresponsiveness [115,116].”
Afsar, T., Razak, S., Almajwal, A. M., Shabbir, M., Khan, K., Trembley, J. H., & Alruwaili, N. W. (2022) · AMB Express · doi:10.1186/s13568-022-01501-y · Cited by 18
Kulkarni, T., Criner, G. J., Kass, D. J., Rosas, I. O., Scholand, M. B., Dilling, D. F., Summer, R. S., & Duncan, S. R. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-02957-3 · Cited by 16
“Recent studies have revealed several parallels between conventional autoimmune syndromes and progressive IPF [13–19].”
BackgroundSelf-citationClinical experience in idiopathic pulmonary fibrosis: a retrospective study
Guiot, J., Duysinx, B., Seidel, L., Henket, M. A., Gester, F., Bonhomme, O., Corhay, J.-L., & Louis, R. E. (2017) · Acta Clinica Belgica · doi:10.1080/17843286.2017.1399228 · Cited by 18
Scheible, K. M., Secor‐Socha, S., Wightman, T., Wang, H., Mariani, T. J., Topham, D. J., Pryhuber, G., & Quataert, S. A. (2012) · Cytometry Part A · doi:10.1002/cyto.a.22203 · Cited by 15
“Loss of CD28 expression on CD41 T cells is associated with cells that have undergone multiple cycles of proliferation and terminally differentiated into IFNc effectors or into a senescent phenotype (20).”
BackgroundImmunosuppressive Therapy for Autoimmune Lung Diseases
Meyer, K. C., & Bierach, J. (2012) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2012.07.001 · Cited by 14
Newer developments in idiopathic pulmonary fibrosis in the era of anti-fibrotic medications
NAIR, G. B., Matela, A., Kurbanov, D., & Raghu, G. (2016) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2016.1177461 · Cited by 14
“increased levels of type 2 T helper cell (TH2) inflammation [15,16].”
BackgroundSun, X., Zhang, X., He, Y., Du, X., Cai, Q., & Liu, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1562892 · Cited by 17
Achaiah, A., Fraser, E., Saunders, P., Hoyles, R. K., Benamore, R. E., & Ho, L. (2023) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2023-001801 · Cited by 15
Granzyme B PET Imaging of the Innate Immune Response
Capaccione, K. M., Doubrovin, M., Bhatt, N., Mintz, A., & Molotkov, A. (2020) · Molecules · doi:10.3390/molecules25133102 · Cited by 12
“We performed anti-granzyme B IF on LPS (Figure 2A,C) and PBS (Figure 2C,E) treated tissue which demonstrated differential staining of granzyme B in LPS-treated compared to PBS-treated mice, similar to prior studies [18,21].”
MethodResultA Human-Mouse Chimeric Model of Obliterative Bronchiolitis after Lung Transplantation
Xue, J., Zhu, X., George, M. P., Myerburg, M. M., Stoner, M. W., Pilewski, J., & Duncan, S. R. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.04.014 · Cited by 12
Self-citationThe Role of Immunity and Inflammation in IPF Pathogenesis
Butler, M. W., & Keane, M. P. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_6 · Cited by 14
Beltramo, G., Thabut, G., Péron, N., Nicaise‐Roland, P., Cazes, A., Debray, M., Joannes, A., Castier, Y., Mailleux, A., Frija‐Masson, J., et al. (2018) · Respiratory Medicine · doi:10.1016/j.rmed.2017.12.011 · Cited by 11
Xia, Y., Lei, C., Yang, D., & Luo, H. (2020) · PeerJ · doi:10.7717/peerj.9848 · Cited by 11
“Furthermore, many studies have also confirmed that changes in immune activity or the proportions of immune cell populations may be associated with declines in lung function (Adegunsoye et al., 2016; Gilani et al., 2010; Xue et al., 2013).”
BackgroundSandbo, N. K. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-682-5_8 · Cited by 13
Immune mechanisms and novel therapies for idiopathic pulmonary fibrosis
Gao, D., Gao, W., Zhai, Z., & Zhu, W. (2023) · Pharmaceutical Science Advances · doi:10.1016/j.pscia.2023.100030 · Cited by 9
Management of interstitial lung disease in elderly patients
Meyer, K. C. (2012) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e3283541337 · Cited by 10
“low numbers of CD4þ T cells and CD19þ B cells plus impaired T-cell proliferative response and increased numbers of CD3þ cytotoxic/suppressor cells) have been associated with frailty and shortened lifespan [8], and another immune signature, downregulation of CD28 on circulating CD4 T cells, is associated with worse out…”
BackgroundFang, C., Huang, H. F., Feng, Y., Zhang, Q., Wang, N., Jing, X., Guo, J., Ferianc, M., & Xu, Z. (2021) · Scientific Reports · doi:10.1038/s41598-020-80944-4 · Cited by 9
Atanasova, E. A., Milosevic, D., Bornschlegl, S., Krucker, K., Jacob, E. K., Carmona, E. M., Anderson, D. K., Egan, A. M., LIMPER, A. H., & Dietz, A. B. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02692-0 · Cited by 10
Eight-color panel for immune phenotype monitoring by flow cytometry
Cardoso, C. C., & Santos‐Silva, M. C. (2019) · Journal of Immunological Methods · doi:10.1016/j.jim.2019.03.010 · Cited by 9
Is personalized medicine a realistic goal in idiopathic pulmonary fibrosis?
Thannickal, V. J., & Antony, V. B. (2018) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2018.1464913 · Cited by 9
Zhong, B., Zhou, J. Q., Lyu, X., Liu, H., Yuan, K., Guo, M., Duncan, S. R., & Sanders, Y. Y. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2400106 · Cited by 8
Self-citationEnomoto, N., Chida, K., Suda, T., Kaida, Y., Taniguchi, M., Azuma, A., Hayashi, H., Ogura, T., Kitamura, H., Yamaguchi, O., et al. (2015) · The Clinical Respiratory Journal · doi:10.1111/crj.12281 · Cited by 8
CD4+ T Cell Defects in a Mulibrey Patient With Specific TRIM37 Mutations
Bruzzaniti, S., Cirillo, E., Prencipe, R., Giardino, G., Lepore, M. T., Garziano, F., Perna, F., Procaccini, C., Mascolo, L., Pagano, C., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01742 · Cited by 8
“In this context, it has been shown that repeated cycles of proliferation determine the disappearance of cell-surface CD28 molecules (27), suggesting this as the basis of CD4CD28 cell reduction observed in the MUL case.”
BackgroundVelez, T. E., Yoon, Y. M., Upadhyay, V., Vazquez, S. E., Lee, C. T., Selvan, K. C., Law, C. S., Blaine, K. M., Hollinger, M. K., Decker, D. C., et al. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202502-0419oc · Cited by 9
CD70 Activation Decreases Pulmonary Fibroblast Production of Extracellular Matrix Proteins
Tran-Nguyen, T. K., Xue, J., Feghali‐Bostwick, C. A., Sciurba, F. C., Kass, D. J., & Duncan, S. R. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0450oc · Cited by 9
Self-citationГоловкин, А. С., Kudryavtsev, I. V., Dmitriev, A. V., & Kalinina, O. (2020) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2020-4087 · Cited by 10
Immunobiology of pulmonary fibrosis
Bindu, S., Yasmin, H., Barman, U., Pandit, S., Masmoudi, K., & Kishore, U. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1708716 · Cited by 7
Cellular mechanisms in the pathogenesis of interstitial lung diseases
Singh, P., Ali, S. N., Zaheer, S., & Singh, M. P. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154691 · Cited by 9
Biomarkers in Idiopathic Pulmonary Fibrosis
Sood, S., Russell, T. D., & Shifren, A. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_10 · Cited by 7
Kass, D. J., Flynn, M., & Baker, E. (2015) · Current Biomarker Findings · doi:10.2147/cbf.s81362 · Cited by 7
“Markedly decreased expression of CD28, a necessary component of T-cell activation, on the surface of CD4+ T-cells was correlated with a more severe 1-year outcome in IPF.(103) These findings were supported further by genomic analysis of peripheral blood mononuclear cells from two separate IPF cohorts that showed that…”
Zhao, H. Z., Wang, L., Yan, Y., Zhao, Q.-H., He, J., Jiang, R., Luo, C., Qiu, H., Miao, Y., Gong, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1197752 · Cited by 5
“Previous studies have already described a specific depletion of CD4 + T cells in peripheral venous blood of patients with PH (34) and PF (35); this significant downregulation is associated with poor outcomes in patients with PF (35) and PH (36).”
BackgroundProteomic analysis of serum samples of paracoccidioidomycosis patients with severe pulmonary sequel
dos Santos, A. R., Dionizio, A. S., Fernandes, M. D. S., Buzalaf, M. A. R., Pereira, B. A. S., Donanzam, D. D. F. A., Ribeiro, S. M., Paniago, A. M. M., Cavalcante, R. D. S., Mendes, R. P., et al. (2021) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0009714 · Cited by 8
Lin, Y., Lai, X., Huang, S., Pu, L., Zeng, Q., Wang, Z., & Huang, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1078055 · Cited by 5
“According to the majority of studies, it has been concluded that an increase in the frequency or activation of certain T cells and B cells is associated with the progression of IPF (12, 13, 45).”
BackgroundYunt, Z. X., Aschner, Y., & Brown, K. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54431-3.00010-x · Cited by 6
The Role of Adaptive Immunity in Idiopathic Pulmonary Fibrosis: Hiding in Plain Sight
Duncan, S. R. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-682-5_7 · Cited by 4
Self-citationRisk Factors and Biomarkers of RA-ILD
Doyle, T. J., Dellaripa, P. F., & Rosas, I. O. (2017) · Respiratory medicine · doi:10.1007/978-3-319-68888-6_5 · Cited by 4
Sergeevichev, D., Balashov, V. A., Kozyreva, V. S., Pavlova, S. V., Vasiliyeva, M., Romanov, A., & Chepeleva, E. V. (2022) · Journal of Functional Biomaterials · doi:10.3390/jfb13010006 · Cited by 3
“One of the earliest mechanisms of transplant immunity manifestation is activation of the CD28/B7/CTLA-4 - receptor complex on lymphocytes and antigen-presenting cells (APCs) [30-32].”
BackgroundInterstitial lung diseases: an overview
Karampitsakos, Τ., Wijsenbeek, M. S., Herazo‐Maya, J. D., Τzouvelekis, Α., & Kreuter, M. (2023) · European Respiratory Society eBooks · doi:10.1183/2312508x.10017322 · Cited by 3
T Regulatory Mechanisms in Airway and Interstitial Lung Disease
Pastore, C., Stadler, B. D., Sperling, A. I., & Velez, T. E. (2025) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/a-2703-4491 · Cited by 3
Targeting immunosenescence in lung diseases: mechanistic insights and clinical interventions
Zhang, Y., Yu, X., Li, P., Ouyang, Y., Zhu, L., & Luo, F. (2026) · BMC Medicine · doi:10.1186/s12916-026-04833-9 · Cited by 2
“CD4 ⁺ CD28 − T cells have also been detected in both BALF and lung transplant tissues of patients with IPF, with increased cell accumulation significantly correlating with poor prognosis [147].”
Expression of CD28 in Hepatocellular Carcinoma and Its Prognostic Value
Ran, X., Zhang, C., Wang, X., Zhao, Q. S., Zhao, Q., Yuan, C., Kuang, Y., Chen, X., & Chen, X. (2022) · Hepatitis Monthly · doi:10.5812/hepatmon.118605 · Cited by 2
Aging in COPD and Idiopathic Pulmonary Fibrosis
Sánchez, C. G. (2015) · Springer eBooks · doi:10.1007/978-3-319-23246-1_15 · Cited by 2
Diversity of CD28null T Cells in the Elderly: A Glimpse in a Biological Adaptation of Aging
Griffin, P. C., Michel, J. J., & Vallejo, A. N. (2017) · Springer eBooks · doi:10.1007/978-3-319-64597-1_87-1 · Cited by 2
The HLA Class II Allele DRB1*1501 Is Over-Represented In Patients With Idiopathic Pulmonary Fibrosis
Xue, J., Gochuico, B. R., Feghali‐Bostwick, C. A., Noth, I., Nathan, S. D., Rosen, G., Rosas, I. O., Gibson, K. F., Kaminski, N., Sciurba, F. C., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a4272 · Cited by 2
Self-citationAcute exacerbation of idiopathic pulmonary fibrosis disease: a diagnosis model in China
Meng, L., Xiao, J., Wang, L., & Huang, Z. (2024) · European journal of medical research · doi:10.1186/s40001-024-01791-x · Cited by 2
“Decreased CD4 + CD28 + T cells, decreased Treg cells had been revealed with worse prognosis and more severe disease in IPF patients by several studies [25, 26].”
Maciejewska-Radomska, A., Czernia, P., Piotrowska, M., Wajda, B., Słomiński, B., Romantowski, J., Sudoł, A., Dabrowska, M. E., Górska, L., Smiatacz, T., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1436491 · Cited by 1
Kass-Gergi, S., Holcomb, N. P., Maiden, M. M., Eisenlohr, L. C., & Vaughan, A. E. (2025) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00189.2025 · Cited by 2
“T cell function in PF is complex given different subsets exhibit profibrotic, antifibrotic, or neutral functions (83–85).”
The Role of Autoimmunity in the Pathogenesis of Obliterative Bronchiolitis
Braun, R., Meyer, K. C., & Burlingham, W. J. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7636-8_10 · Cited by 1
“[22] correlated with more aggressive disease.”
Pathogenesis and New Diagnosis Guideline of Idiopathic Pulmonary Fibrosis
Uh, S. (2013) · Korean Journal of Medicine · doi:10.3904/kjm.2013.84.4.481 · Cited by 1
Diversity of CD28null T Cells in the Elderly: A Glimpse in a Biological Adaptation of Aging
Griffin, P. C., Michel, J. J., & Vallejo, A. N. (2019) · Springer eBooks · doi:10.1007/978-3-319-99375-1_87 · Cited by 1
Peripheral Immune Cell Profiling Reveals Distinct Immune Hallmarks in Progressive Pulmonary Fibrosis
Hernández‐González, F., Mendoza, N., Casas-Recasens, S., Cruz, T., Albacar, N., López-Saiz, G., Alsina‐Restoy, X., Rojas, M. M., Agustí, A. G. N., Sellarés, J., et al. (2023) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2023.06.009 · Cited by 1
Tabaco y alteraciones intersticiales: ¿una asociación plausible?
Albacar, N., Faner, R., & Sellarés, J. (2019) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2019.09.006 · Cited by 1
Smoking and Interstitial Lung Damage/Effects: A Plausible Association?
Albacar, N., Faner, R., & Sellarés, J. (2020) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2019.09.014 · Cited by 1
d’Audigier, C. (2013) · theses.fr (ABES) · doi:10.70675/19800b70z5208z47c4z97e8z80d335c3a541
Korthagen, N. M. (2012) · Utrecht University Repository (Utrecht University)
Regulation of liver X receptors by microRNA-155 in pulmonary fibrosis
Hasoo, M. K. (2013) · Enlighten: Theses (The University of Glasgow)
Idiopathische pulmonale Fibrose: Diagnostik und prognostische Beurteilung
Poletti, V. E., Ravaglia, C., Buccioli, M., Tantalocco, P., Piciucchi, S., Dubini, A., Carloni, A., Chilosi, M., & Tomassetti, S. (2014) · Kompass Pneumologie · doi:10.1159/000358357
Optimization of Lentivirus Production for Cancer Therapy
Camacho, E. (2011) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Idiopathic Pulmonary Fibrosis, Opportunities and Challenges
Ernst, G., Borsini, E. E., & Alejandro, S. (2015) · Clinical Anti-Inflammatory & Anti-Allergy Drugs · doi:10.2174/2212703802666150127002032
“Moreover, they described a relationship between the increase of cells CD4-CD28 low and a worse clinical status of IPF patients [31].”
BackgroundGenomics of Lung Aging and Idiopathic Pulmonary Fibrosis
Juan-Guardela, B. M., & Kaminski, N. (2015) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814635011_0015
Self-citationVuga, L. J. (2016) · D-Scholarship@Pitt (University of Pittsburgh)
Self-citationFuture Directions in Basic and Clinical Science
Mikacenic, C. R., & Raghu, G. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-682-5_21
Role of Immune Checkpoint Proteins in Idiopathic Pulmonary FibrosisPreprint
Habiel, D. M., Espíndola, M. S., Kitson, C., Azzara, A. V., Coelho, A. L., & Hogaboam, C. M. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/173237
Blandinières, A. (2018) · theses.fr (ABES) · doi:10.70675/9178d6fcz7e4ez48deza1dcz0840f8c96b22
Morphological and functional studies in a sheep model of pulmonary fibrosis
Dewage, V., & Nimanthi, S. (2020) · Minerva Access (University of Melbourne)
Mechanisms of myeloid cell recruitment and biomarker potential in interstitial lung diseases
Greiffo, F. R. (2019) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.25155
Uh, S. (2013) · Korean Journal of Medicine
Idiopathic Pulmonary Fibrosis Clinical Trials: Evolving Concepts
Martínez, F. J. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-682-5_20 · Cited by 1
(2010) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3283404094
Sandbo, N. K. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_7
Xu, Q., Zhang, M., Tang, M., Li, Z., Liu, Y., Rao, Z., Yang, K., He, X., Ma, R., & Xue, X. (2022) · Research Square · doi:10.21203/rs.3.rs-2092293/v1
Xu, Q., Zhang, M., Tang, M., Li, Z., Liu, Y., ma, T., Rao, Z., Yang, K., He, X., Ma, R., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2245802/v1
Rôle de l'immunomodulateur P2RX7 dans le cancer et la fibrose pulmonaire
Hreich, S. J. D. (2022) · theses.fr (ABES) · doi:10.70675/4b399e7fzb436z4e8fz8045z90c0862c799d
Additional file 1 of PTK2-associated gene signature could predict the prognosis of IPF
Feng, A., Caro, Y. M., Gardner, C., Grischo, G., Liang, Y., Wickremasinghe, P. D., Polmann, M. B., Kala, M., Marlowe, T. A., Black, S. M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24751209
Additional file 2 of PTK2-associated gene signature could predict the prognosis of IPF
Feng, A., Caro, Y. M., Gardner, C., Grischo, G., Liang, Y., Wickremasinghe, P. D., Polmann, M. B., Kala, M., Marlowe, T. A., Black, S. M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.24751664
Afsar, T., Razak, S., Almajwal, A., Shabbir, M., Khan, K., Trembley, J. H., & Alruwaili, N. (2024) · Figshare · doi:10.6084/m9.figshare.26554796
Additional file 4 of PTK2-associated gene signature could predict the prognosis of IPF
Feng, A., Caro, Y. M., Gardner, C., Grischo, G., Liang, Y., Wickremasinghe, P. D., Polmann, M. B., Kala, M., Marlowe, T. A., Black, S. M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26650098
Additional file 6 of PTK2-associated gene signature could predict the prognosis of IPF
Feng, A., Caro, Y. M., Gardner, C., Grischo, G., Liang, Y., Wickremasinghe, P. D., Polmann, M. B., Kala, M., Marlowe, T. A., Black, S. M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26650104
Ghosh, A. J., Hobbs, B. D., Yun, J. H., Saferali, A., Moll, M. R., Xu, Z., Chase, R. P., Morrow, J. D., Ziniti, J. P., Sciurba, F., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19634917
Meng, L., Xiao, J., Wang, L., & Huang, Z. (2024) · Figshare · doi:10.6084/m9.figshare.26697557
Metadata
- Authors
- Gilani, S. R., Vuga, L. J., Lindell, K. O., Gibson, K. F., Xue, J., Kaminski, N., Valentine, V. G., Lindsay, E. K., George, M. P., Steele, C., & Duncan, S. R.
- Affiliations
- University of Pittsburgh (US)
- The University of Texas Medical Branch at Galveston (US)
- University of Alabama at Birmingham (US)
- Corresponding author
- Duncan, Steven R.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-01-29
- Volume
- 5
- Issue
- 1
- Pages
- e8959
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2813297
- OpenAlex
- W1976574577
- Cited by
- 203
- References
- 54
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 15 · 2023: 14 · 2022: 11 · 2021: 12 · 2020: 9 · 2019: 9 · 2018: 18 · 2017: 14 · 2016: 11 · 2015: 14 · 2014: 13 · 2013: 18 · 2012: 18
- FWCI
- 13.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- D-Scholarship@Pitt (University of Pittsburgh) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- University of Pittsburgh
- National Institutes of Health (5r01hl073241-04, 5p50hl084932-05)
- National Heart, Lung, and Blood Institute (R01 HL073241, P50-HL-084932, 1P50 HL084932, 1R01HL073241, T32HL007563)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- idiopathic pulmonary fibrosis, CD4+ T cells, T cell exhaustion, prognostic factors, perforin, granzyme B, Foxp3+ regulatory T cells, inflammatory cytokines, lung transplantation, forced vital capacity, adaptive immune activation, lung infiltration, major adverse clinical events, T cell activation markers
- MeSH terms
- Adult, Humans, Male, Prognosis, Pulmonary Fibrosis, CD4-Positive T-Lymphocytes, Down-Regulation, CD28 Antigens
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.